AntiCancer, Inc., San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.
Anticancer Res. 2021 Dec;41(12):5865-5871. doi: 10.21873/anticanres.15406.
BACKGROUND/AIM: Recurrent osteosarcoma is recalcitrant with poor response rates to first-line chemotherapy due to heterogeneity and metastatic potential. This disease requires novel drug discovery and precision treatment.
The osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model mimics the clinical disease and has identified effective clinically-approved drugs and experimental agents, especially drug combinations, that hold much clinical promise.
Effective treatment for drug-resistant osteosarcoma includes regorafenib, as monotherapy, and temozolomide-irinotecan, trabectedin-irinotecan, sorafenib-everolimus, sorafenib-palbociclib, and olaratumab-doxorubicin-cisplatinum, as combinations.
The PDOX model can be used to improve the outcome of osteosarcoma patients, including individualized, precision therapy.
背景/目的：复发性骨肉瘤具有异质性和转移性潜能，对一线化疗的反应率较差，治疗效果不佳。这种疾病需要新的药物发现和精准治疗。
骨肉瘤患者来源的原位异种移植（PDOX）小鼠模型模拟了临床疾病，并已确定有效的临床批准药物和实验药物，特别是药物组合，具有很大的临床应用前景。
针对耐药性骨肉瘤的有效治疗方法包括regorafenib 单药治疗，以及替莫唑胺-伊立替康、trabectedin-irinotecan、索拉非尼-依维莫司、索拉非尼-palbociclib 和奥拉单抗-多柔比星-顺铂联合治疗。
PDOX 模型可用于改善骨肉瘤患者的预后，包括个体化、精准治疗。
